Home / Pharma Healthcare / Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Pipeline Review, H1 2017

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Pipeline Review, H1 2017

  • Id : RNR-94918
  • Category : Pharma Healthcare
  • Publish Date : 13-Jun-2017
  • Pages : 73
  • Format : PDF
License Type

Description
Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Pipeline Review, H1 2017

Summary

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Proto-oncogene tyrosine-protein kinase Src or proto-oncogene c-Src is a non-receptor tyrosine kinase protein that is encoded by the SRC gene. It participates in signaling pathways that control a diverse spectrum of biological activities including gene transcription, immune response, cell adhesion, cell cycle progression, apoptosis, migration, and transformation. Due to functional redundancy between members of the SRC kinase family, identification of the specific role of each SRC kinase is very difficult. It plays a role in the activation of other protein tyrosine kinase (PTK) families. It plays an important role in the regulation of cytoskeletal organization through phosphorylation of specific substrates such as AFAP1. 

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) pipeline Target constitutes close to 12 molecules. Out of which approximately 11 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 5 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Gastrointestinal, Respiratory, Central Nervous System, Immunology, Musculoskeletal Disorders and Ophthalmology which include indications Solid Tumor, Lymphangioleiomyomatosis, Non-Small Cell Lung Cancer, Ulcerative Colitis, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Alcohol Addiction, Alzheimer's Disease, Bladder Cancer, Breast Cancer, Cancer Pain, Cervical Cancer, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Endometrial Cancer, Epithelial Ovarian Cancer, Esophageal Cancer, Fallopian Tube Cancer, Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Hepatocellular Carcinoma, Interstitial Lung Fibrosis, Keratoconjunctivitis sicca (Dry Eye), Liver Cancer, Lung Adenocarcinoma, Lung Cancer, Malignant Pleural Mesothelioma, Medullary Thyroid Cancer, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Melanoma, Metastatic Renal Cell Carcinoma, Neuroendocrine Tumors, Non-Hodgkin Lymphoma, Pancreatic Cancer, Peritoneal Cancer, Prostate Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Small-Cell Lung Cancer, Soft Tissue Sarcoma, Squamous Non-Small Cell Lung Cancer, Systemic Sclerosis (Scleroderma) and Transitional Cell Carcinoma (Urothelial Cell Carcinoma). 

The latest report Proto Oncogene Tyrosine Protein Kinase Src - Pipeline Review, H1 2017, outlays comprehensive information on the Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2)
- The report reviews Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it?s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope